BIOTECH

We are going to take a close look at () today to get a better sense of the company and its current status, as well as the opportunity it may offer for prospective investors. Today's focus will be a fundamental evaluation of the stock from top to bottom. As...

Merck & Co., Inc. (NYSE:MRK) Zovastak, the shingles vaccine developed by Merck has increasingly come under a wave of lawsuits following claims that it is causing serious injury and sometimes even death. Plaintiffs in the lawsuits are now suing Merck for not warning them of the vaccine’s severe side...

Replicel Life Sciences (OTCQB: REPCF) The stem cell revolution is finally here, and it’s transforming modern medicine.  Investors are flocking to this small-cap company with treatments for hair restoration, skin rejuvenation, and tendon repair.  When we stumbled upon Replicel Life Sciences (OTCQB: REPCF and TSX.V:RP) it really caught our attention. ...

Exelixis, Inc. (NASDAQ:EXEL) has released their financials results for the 4Q2016 and FY2016. The company also provided an update on its corporate objectives and upcoming milestones. For its 4Q2016, EXEL recorded a net income of $35.1 million, as compared to a net loss for 4Q2015. Exelixis was able to...

Before we go into details of Delcath Systems, Inc. (NASDAQ:DCTH), a biotech company that needs your immediate attention is OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP). OBMP is a clinical stage biopharmaceutical company that develops cancer immunotherapy products. The company has proprietary rights to a breast and prostate patent vaccine; and a process...

Array Biopharma Inc (NASDAQ:ARRY) a biopharmaceutical firm focused on the development, commercialization and discovery of targeted small molecule cancer treatments reported financial results for 2Q2017 and released an update on the development of its major clinical development plans. Ron Squarer, the CEO, reported that they are delighted to announce that...

In the last trading session, the stock price of Novavax, Inc. (NASDAQ:NVAX) gained over 14% to close the session at $1.62 on more than normal volume. No specific news accounts for this move. Last month, it commenced a Phase II clinical study evaluating the immunogenicity and safety of its...

Shares of (NASDAQ:) are currently up by more than from the open today and are trading at $. More than shares have exchanged hands compared to an average trading volume of . At the current pps, the market cap stands at $. The stock prices of...

Shares of (NASDAQ:) are currently up by more than from the open today and are trading at $. More than shares have exchanged hands compared to an average trading volume of . At the current pps, the market cap stands at $. The stock prices of...

Shares of (NASDAQ:) are currently up by more than from the open today and are trading at $. More than shares have exchanged hands compared to an average trading volume of . At the current pps, the market cap stands at $. The stock prices of...